Affinia Therapeutics Presents New Preclinical Data on Novel AAV Capsids for Skeletal Muscle, Cardiac Muscle, and CNS at the American Society of Gene & Cell Therapy 26TH Annual Meeting
WALTHAM, Mass., May 18, 2023 /PRNewswire/ — Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for both rare and prevalent devastating diseases, today announced the presentation of new preclinical data on novel AAV capsids for skeletal muscle, cardiac muscle, and central nervous system (CNS). This research will be presented in an oral session today at 1:30pm PT … Read more